Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4Carcinoid Tumor 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenoma, Islet Cell 1Adenocarcinoma 1Acromegaly 1

Interventions

Fluorouracil 11Gemcitabine 8pembrolizumab 7Leucovorin 7Irinotecan 7Paclitaxel 6Oxaliplatin 5Carboplatin 5130-nm albumin-bound paclitaxel 5Nivolumab 4Cisplatin 4Albumin-Bound Paclitaxel 4Taxes 3Ramucirumab 3Radiosurgery 3Pemetrexed 3Docetaxel 3Capecitabine 3Bevacizumab 3vandetanib 2spartalizumab 2selinexor 2osimertinib 2folfirinox 2Radiation 2Cyclophosphamide 2zolbetuximab 1trastuzumab deruxtecan 1trametinib 1tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma × pasireotide × Clear all
NCT01385956 2020-09-28

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡